Item 7.01 Regulation FD Disclosure.
On January 8, 2023, Viridian Therapeutics, Inc. issued a press release
announcing, and made available a presentation regarding, positive topline data
from its Phase 1/2 trial of VRDN-001 in patients who suffer from thyroid eye
disease. The press release and data presentation are attached hereto as Exhibits
99.1 and 99.2, respectively, which are furnished under Item 7.01 of this Current
Report on Form 8-K and shall not be deemed to be "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall they
be deemed incorporated by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, regardless of any general incorporation
language in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit
Number Exhibit Description
99.1 Press release regarding topline data, dated January 8, 2023
99.2 Viridian Therapeutics, Inc. Topline Data Presentation, dated January
2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses